The Department of Molecular Medicine in the Institute of Biotechnology (IBT) was established in 1994 to administer a program to train graduate students at the interface of basic and clinical sciences with an emphasis on biomedical research focused on discovering the molecular mechanisms underlying human disease and to serve as a platform for the development of novel treatment or prevention approaches. To date, our program has awarded over 120 doctoral degrees. Our graduates are placed in top-tier research universities and pharmaceutical companies across the United States and Europe. Our faculty have been successful in securing tens of millions of dollars from private and federal agencies including the National Institutes of Health, the National Science Foundation, and the Department of Defense.
Now also located in the South Texas Research Facility (STRF), we offer a research-oriented, interdisciplinary program of study in the areas of cancer and aging and their prevention. Specific areas of study include: cell (and hormone) signaling, gene expression, epigenetics, cell cycle and checkpoint controls, DNA damage repair and associated stress responses, and regulated protein turnover. Under new leadership, Dr. Tim Huang is expanding our research to include a Systems approach to molecular medicine that offers students an integrated training program spanning molecular and cellular biology, quantitative biology, computational biology, and genomics.
Our goal is to educate and train the next generation of graduate students who will change the face of biomedical research and invent new ways to treat and prevent human diseases.
Recent Publications with High Impact Factors
Xiaowen Zhang, Huai-Chin Chiang, Yao Wang, Chi Zhang, Sabrina Smith, Xiayan Zhao, Sreejith J. Nair, Joel Michalek, Ismail Jatoi, Meeghan Lautner, Boyce Oliver, Howard Wang, Anna Petit, Teresa Soler, Joan Brunet, Francesca Mateo, Miguel Angel Pujana, Elizabeth Poggi, Krysta Chaldekas, Claudine Isaacs, Beth N. Peshkin, Oscar Ochoa, Frederic Chedin, Constantine Theoharis, Lu-Zhe Sun, Tyler J. Curiel, Richard Elledge, Victor X. Jin, Yanfen Hu & Rong Li. (2017). Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nature Communications. 8, 15908 doi:10.1038/ncomms15908.
Araki, K., Morita, M., Bederman, A. G., Konieczny, B. T., Kissick, H. T., Sonenberg, N., & Ahmed, R. (2017). Translation is actively regulated during the differentiation of CD8 effector T cells. Nature Immunology. doi:10.1038/ni.3795
Hsu Y-T, Osmulski, P.A., Wang Y., Huang Y-W, Liu L., Ruan J., Jin V.X., B. Kirma N.B., Gaczynska M. E., and Huang T. H-M (2017) EGFR-Dependent Regulated Intramembrane Proteolysis of EpCAM-Response. Cancer Res. 77 (7):1777.
Huang RL, Su PH, Liao YP, Wu TI, Hsu YT, Lin WY, Wang HC, Weng YC, Ou YC, Huang TH, Lai HC (2017) Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings. Clin Cancer Res 23(1):263-272.
Noonepalle SK, Gu F, Lee EJ, Choi JH, Han Q, Kim J, Ouzounova M, Shull AY, Pei P, Hsu PY, Kolhe R, Shi F, Choi J, Chiou K, Huang HM, Korkaya H, Deng L, Xin HB, Huang S, Thangaraju M, Sreekumar A, Ambs S, Tang SC, Munn DH, Shi H (2017) Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers. Cancer Immunology Research 5 (4) 330-344
Recently Awarded Grants
A Dual Function Switch in reproductive biology NIH – National Cancer Institute, 8/1/17, $228,750 Rong Li, Ph.D. and Yanfen Hu, Ph.D.
Crosstalk between BRCA1 and transcription in breast cancer NIH – National Cancer Institute, 7/10/17, $411,463 Rong Li, Ph.D.
Understanding Drug Resistance in BRCA1 Associated Cancer Therapy Army Medical Research Acquisition Activity, 9/30/17, $583,314 Yanfen Hu, Ph.D.
Understanding Drug Resistance in BRCA1 Associated Cancer Therapy Army Medical Research Acquisition Activity, 9/30/17, $331,689 Rong Li, Ph.D.
Targeting Enhancer Activation Machinery in Breast Cancer Hormone Resistance Voelcker Fund, 7/1/17, $450,000 Zhijie Liu, Ph.D.
Systems Analysis of Epigenomic Architecture in Cancer Progression NIH – National Cancer Institute, 5/15/17, $9,119,402 Tim Huang, Ph.D.& Victor Jin, Ph.D.
Precision Targeting of MED12-Mutant CLL with Notch Inhibitors William & Ella Owens Foundation of America, 3/15/17, $100,000 Thomas Boyer, Ph.D.
Regulation of ER-Beta Signaling in Carcinogenesis NIH – National Cancer Institute, 2/1/17, $2,397,840 Rong Li, Ph.D.
Molecular Medicine – Graduate School of Biomedical …